Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 415

Similar articles for PubMed (Select 19125776)

1.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

Idris I, Donnelly R.

Diabetes Obes Metab. 2009 Feb;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. Review.

PMID:
19125776
2.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
3.

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Jabbour SA, Goldstein BJ.

Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x. Review.

PMID:
18705823
4.

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

DeFronzo RA, Davidson JA, Del Prato S.

Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x. Review.

PMID:
21955459
5.

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.

6.

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.

Chen LH, Leung PS.

Diabetes Obes Metab. 2013 May;15(5):392-402. doi: 10.1111/dom.12064. Epub 2013 Feb 6. Review.

PMID:
23331516
7.

Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus.

Vaidya HB, Goyal RK.

Mini Rev Med Chem. 2010 Sep;10(10):905-13. Review.

PMID:
21034414
8.
9.

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. doi: 10.1517/13543780902766794 . Review.

PMID:
19243283
10.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.

Washburn WN.

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Review.

PMID:
19852718
11.

SGLT2 inhibition--a novel strategy for diabetes treatment.

Chao EC, Henry RR.

Nat Rev Drug Discov. 2010 Jul;9(7):551-9. doi: 10.1038/nrd3180. Epub 2010 May 28. Review.

PMID:
20508640
12.

SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.

Deshmukh AB, Patel MC, Mishra B.

Ren Fail. 2013;35(4):566-72. doi: 10.3109/0886022X.2013.766560. Epub 2013 Feb 25. Review.

PMID:
23438184
13.

Sodium-glucose cotransporter inhibitors for diabetes.

Isaji M.

Curr Opin Investig Drugs. 2007 Apr;8(4):285-92. Review.

PMID:
17458177
14.

SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.

Misra M.

J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9. Review.

PMID:
23356840
15.

A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.

Basile J.

Postgrad Med. 2011 Jul;123(4):38-45. doi: 10.3810/pgm.2011.07.2302. Review.

PMID:
21680987
16.

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors.

Patel AK, Fonseca V.

Curr Diab Rep. 2010 Apr;10(2):101-7. doi: 10.1007/s11892-010-0095-5. Review.

PMID:
20425568
17.

Dapagliflozin for the treatment of type 2 diabetes.

Brooks AM, Thacker SM.

Ann Pharmacother. 2009 Jul;43(7):1286-93. doi: 10.1345/aph.1M212. Epub 2009 Jul 7. Review.

PMID:
19584379
18.

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

Pérez López G, González Albarrán O, Cano Megías M.

Nefrologia. 2010;30(6):618-25. doi: 10.3265/Nefrologia.pre2010.Sep.10494. Review. Spanish.

19.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk